Testosterone Science

Alternatives to Testosterone Therapy

Enclomiphene: The TRT Alternative Explained: How It Works, the Evidence and Its Regulatory Status

Specific Claim Evaluated

Enclomiphene has never been approved by the FDA, EMA or MHRA; in short randomized trials sperm concentration was essentially unchanged, but no trial measured pregnancy or live birth and the trials did not show a convincing symptom benefit over placebo.

Primary Research Supporting or Contradicting the Claim

In 2 parallel phase 3 trials in overweight men with secondary hypogonadism, enclomiphene raised total testosterone and maintained sperm concentration in the normal range over 16 weeks, while testosterone gel reduced sperm concentration; pregnancy was not an end point (Kim et al., 2016).

Corrected Evidence-Based Interpretation

The article is correct. Enclomiphene raises testosterone and preserves sperm concentration over months, but its effect on fertility outcomes and long-term safety is unknown.

Rationale for Grade

The article separates hormonal and semen end points from clinical outcomes, states the regulatory status accurately and identifies the absence of long-term data. Its date fields are inconsistent, but the content is consistent with the primary trials.

References

  1. Kim ED, McCullough A, Kaminetsky J. Oral enclomiphene citrate raises testosterone and preserves sperm counts in obese hypogonadal men, unlike topical testosterone: restoration instead of replacement. BJU Int. 2016;117(4):677-685. PMID
    Supporting excerpt: "Enclomiphene citrate treatment maintained sperm concentrations in the normal range."

Post a Comment

Shared Decision Making

Bring the Evidence to Your Next Consultation

Use our patient resources and questionnaires to prepare questions about symptoms, testing and treatment options for your doctor.